To evaluate the benefit of combining gedatolisib with an ER inhibitor (fulvestrant) and/or a CDK4/6 inhibitor (palbociclib), we initially screened a panel of nine ER + BC cell lines with various PAM pathway mutational status. Here, CDK4 is linked to breast cancer.